News Focus
News Focus
icon url

masterlongevity

06/20/12 10:18 PM

#144187 RE: mcbio #144186

i agree but prodromal is better than mild to moderate. IF there is a sign of clinical efficacy in the mild subset of bapineuzumab or solanezumab, then prodromal may prove successful